Selected Grants
Ferroptosis and Ferroptotic Stress in Maladaptive Renal Repair - R01
ResearchCollaborator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2023 - 2028Manipulating normal estrogen physiology as a therapeutic approach in cancer
ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2023 - 2028Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2022 - 2027Evaluation of the efficacy of a combined regimen including an ER targeted therapy and ICB
ResearchPrincipal Investigator · Awarded by Sermonix Pharmaceuticals · 2023 - 2024HOXB13 as a therapeutic target in prostate cancer
ResearchAssistant Research Professor · Awarded by Prostate Cancer Foundation · 2020 - 2024Ferroptosis and Ferroptotic Stress in Maladaptive Renal Repair - R01
ResearchCollaborator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2023 - 2028Manipulating normal estrogen physiology as a therapeutic approach in cancer
ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2023 - 2028Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2022 - 2027Evaluation of the efficacy of a combined regimen including an ER targeted therapy and ICB
ResearchPrincipal Investigator · Awarded by Sermonix Pharmaceuticals · 2023 - 2024HOXB13 as a therapeutic target in prostate cancer
ResearchAssistant Research Professor · Awarded by Prostate Cancer Foundation · 2020 - 2024Regulatory principles of the Warburg Effect
ResearchCollaborator · Awarded by American Cancer Society, Inc. · 2017 - 2023Cancer cell intrinsic and extrinsic actions of steroid hormones in breast tumors
ResearchAssistant Research Professor · Awarded by Department of Defense · 2018 - 2023Evaluation of SGK as a therapeutic target in models of breast and prostate cancer
ResearchPrincipal Investigator · Awarded by LQT Therapeutics · 2021 - 2022Evaluation of estrogen receptor as a therapeutic target in melanoma, lung and colorectal cancer models
ResearchPrincipal Investigator · Awarded by Zentalis Pharmaceuticals · 2020 - 2022Role of ER RNA Binding Domain in Breast Cancer
ResearchAssistant Research Professor · Awarded by Ribometrix LLC · 2022 - 2022Identification of Novel Targets in Treatment Resistant Prostate Cancer
ResearchAssistant Research Professor · Awarded by Celgene Corporation · 2017 - 2022Evaluation of novel CDK4/6/9 inhibitors in triple negative breast cancer
ResearchPrincipal Investigator · Awarded by SPV Therapeutics, Inc · 2020 - 2020Developing in vivo active probes for CAMKK2 to treat cancer
ResearchAssistant Research Professor · Awarded by University of North Carolina - Chapel Hill · 2017 - 2020Targeting precursor neural (N)-cadherin to eliminate chemotherapy-resistant triple-negative breast tumor cells
ResearchCo Investigator · Awarded by Department of Defense · 2017 - 2020Targeting differential apoptosis regulation in triple negative breast cancer
ResearchAssistant Research Professor · Awarded by Department of Defense · 2016 - 2019Evaluation of G1 antiestrogens in models of estrogen action
ResearchAssistant Research Professor · Awarded by G1 Therapeutics Inc. · 2018 - 2019Targeting the synthetic essential kinases of breast cancers
ResearchResearch Scientist · Awarded by Department of Defense · 2015 - 2018Evaluating the efficacy of targeting the AGR2 axis in breast and prostate cancer
ResearchPrincipal Investigator · Awarded by Viba Therapeutics · 2017 - 2018Evaluation of the SERD XR5-28 in models of estrogen action
ResearchAssistant Research Professor · Awarded by G1 Therapeutics Inc. · 2016 - 2017Evaluation of G1T38 and SERD XR5-28 in hormone refractory breast cancer
ResearchAssistant Research Professor · Awarded by G1 Therapeutics Inc. · 2016 - 2017Determination of the antiandrogenic properties of VT-464 in models of CRPC
ResearchPrincipal Investigator · Awarded by Innocrin Pharmaceutical, Inc. · 2016 - 2017Evaluation of the therapeutic potential of combining VT464 and G1T38 in treatment-resistant prostate and breast cancer models
ResearchAssistant Research Professor · Awarded by Innocrin Pharmaceutical, Inc. · 2016 - 2017Targeting the CDK 4/6 axis in Castration Resistant Prostate Cancer
ResearchResearch Scientist · Awarded by G1 Therapeutics Inc. · 2015 - 2016Evaluation of VT-464 in AR positive and ER positive breast cancer models
ResearchResearch Scientist · Awarded by Innocrin Pharmaceutical, Inc. · 2015 - 2016Androgen receptor degradation as a therapeutic modality in castrate resistant prostate cancer
ResearchResearch Scientist · Awarded by Arvinas Inc. · 2015 - 2015Determination of the antiandrogenic properties of VT-464, a novel CYP17 lyase inhibitor
ResearchResearch Scientist · Awarded by Viamet Pharmaceuticals · 2014 - 2015Molecular pharmacology of bazedoxifene and pipendoxifene in breast cancer
ResearchResearch Scientist · Awarded by Pfizer, Inc. · 2013 - 2014External Relationships
- Lumanity
- Radius Health
- SPV Therapeutics, Inc.
- Zentalis Pharmaceuticals (formerly Zeno Pharma)
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.